Haemophilia B is a genetic bleeding disorder caused by a shortage of clotting factor IX, one of the proteins your blood needs to form stable clots. It affects roughly 1 in 30,000 male births, making it about six times rarer than haemophilia A, which involves a different clotting protein. Despite their similarities, the two conditions differ in meaningful ways, from severity patterns to treatment options.
How Blood Clotting Normally Works
When you cut yourself or damage a blood vessel, your body kicks off a chain reaction called the clotting cascade. Platelets rush to the site and form a temporary plug, but that plug needs reinforcement. A series of clotting proteins activate one another in sequence until they produce fibrin, a mesh-like material that stabilizes the clot and stops the bleeding.
Factor IX is one link in this chain. It’s produced by the liver and works within what’s called the intrinsic pathway of clotting. When factor IX is missing or not functioning properly, the cascade stalls partway through. The fibrin mesh either forms too slowly, forms incompletely, or doesn’t form at all, leaving you vulnerable to prolonged or uncontrolled bleeding.
Genetics and Inheritance
The gene responsible for producing factor IX (called F9) sits on the X chromosome. Because males have only one X chromosome, a single faulty copy of F9 is enough to cause the disorder. Females have two X chromosomes, so a working copy on one typically compensates for a faulty copy on the other. This is why haemophilia B overwhelmingly affects males, while females are usually carriers who can pass the gene to their children.
A carrier mother has a 50% chance of passing the affected X chromosome to each child. Sons who inherit it will have haemophilia B; daughters who inherit it will generally be carriers. In rare cases, carrier females can experience mild bleeding symptoms if their functional X chromosome is less active than usual. About 7% of haemophilia B cases result from large genetic abnormalities in the F9 gene, a much lower figure than haemophilia A, where gene rearrangements account for nearly half of severe cases. Most F9 mutations are smaller, point-level changes, which has implications for how severe the disease tends to be.
Severity Levels
How serious haemophilia B is depends on how much working factor IX your blood contains. Normal factor IX activity falls between 50% and 150%. The condition is classified into three tiers:
- Severe (less than 1% activity): Frequent spontaneous bleeding, including into joints and muscles without any obvious injury. Typically diagnosed by age 2.
- Moderate (1% to 5% activity): Spontaneous bleeding is less common, but injuries, surgery, and dental work can cause excessive or prolonged bleeding. Usually diagnosed by age 6.
- Mild (above 5% to below 40% activity): Spontaneous bleeding is rare. Problems tend to surface only after major injuries or surgical procedures, and many people aren’t diagnosed until later in life.
People with factor IX activity above 40% generally clot normally in everyday life.
Symptoms and Joint Damage
The hallmark of haemophilia B is bleeding that lasts longer than it should, or bleeding that starts without an obvious cause. External cuts aren’t usually the biggest concern. The more dangerous bleeding happens internally, particularly into joints and soft tissues.
Joint bleeding (hemarthrosis) most commonly hits the knees, which account for about 45% of affected joints, followed by the elbows (30%) and ankles (15%). Shoulders and wrists are involved far less often. Repeated bleeding into the same joint creates a cycle of inflammation and damage that can eventually destroy cartilage and limit mobility. These chronically affected joints are sometimes called “target joints” because the body seems to bleed into them again and again once the cycle starts.
Other symptoms include deep bruising, bleeding into muscles, prolonged bleeding after dental procedures or surgery, and, in rare but serious cases, bleeding inside the skull. In people with severe haemophilia B, bleeding episodes average around 11 per year, though this varies widely.
How Haemophilia B Differs From Haemophilia A
Haemophilia A involves a deficiency of factor VIII rather than factor IX, and it’s far more common, affecting about 1 in 5,000 male births compared to 1 in 30,000 for haemophilia B. On paper, the two conditions look clinically identical: same bleeding patterns, same joint problems, same inheritance model. But recent research suggests haemophilia B may produce a somewhat milder bleeding tendency at equivalent factor levels.
In one large comparative study, people with severe haemophilia A averaged 16 bleeding events per year, while those with severe haemophilia B averaged 11. Joint health scores were also better in severe haemophilia B, and the risk of eventually needing joint replacement surgery was more than three times higher for haemophilia A patients. One possible explanation is that the F9 gene is smaller and structurally simpler, and a higher proportion of its mutations are missense changes (small substitutions that still allow some protein production) rather than the large-scale deletions and rearrangements more common in haemophilia A.
Another important difference is inhibitor development. Inhibitors are antibodies your immune system produces against the replacement clotting factor used in treatment, essentially neutralizing the medication. In haemophilia A, inhibitors develop in 25% to 30% of severe cases. In haemophilia B, that figure drops to just 3% to 5%, likely because factor IX is a smaller protein with fewer sites the immune system can target.
Diagnosis
Haemophilia B is diagnosed through blood tests, starting with screening tests that measure how quickly your blood clots. The key screening test is the activated partial thromboplastin time (APTT), which measures the function of the same clotting pathway factor IX belongs to. In haemophilia B, this test shows a longer-than-normal clotting time. A separate test called prothrombin time (PT) measures a different branch of the clotting system and typically comes back normal in haemophilia B, which helps narrow down the problem.
The definitive step is a factor assay, a blood test that measures the specific activity level of factor IX. This confirms the diagnosis and establishes severity. Because haemophilia A produces similar screening results, the factor assay is essential for distinguishing between the two: a low factor VIII result points to haemophilia A, while a low factor IX result confirms haemophilia B.
Treatment With Factor Replacement
The standard treatment is replacing the missing factor IX through intravenous infusions of commercially prepared clotting factor concentrates. These concentrates come in two forms: plasma-derived products (purified from donated blood) and recombinant products (manufactured in a laboratory without human plasma). Recombinant concentrates carry no risk of transmitting blood-borne viruses.
Treatment can be given on demand, meaning you infuse factor IX when bleeding occurs, or as prophylaxis, meaning you infuse on a regular schedule to maintain enough circulating factor IX to prevent spontaneous bleeding. Prophylaxis is the preferred approach for people with moderate to severe haemophilia B, particularly children, because it protects joints from the cumulative damage of repeated bleeds. Extended half-life factor IX products have made prophylaxis more practical by requiring fewer infusions per week.
Gene Therapy
In November 2022, the FDA approved the first gene therapy for haemophilia B, a single-dose intravenous treatment that delivers a functional copy of the F9 gene directly to liver cells using a modified virus as a delivery vehicle. This was also the first liver-targeted gene therapy of its kind to receive FDA approval.
The therapy uses a specially engineered version of the F9 gene that produces a naturally occurring, hyperactive variant of factor IX, meaning even modest protein production translates into meaningful clotting improvement. In the phase 3 trial of 54 participants, 52 were able to stop their regular factor IX infusions entirely. At 18 months after treatment, average factor IX levels had risen to 37% of normal, well within the range where spontaneous bleeding becomes rare. The number of factor IX infusions dropped by 97%.
The treatment is currently approved for adults with haemophilia B who have been using regular factor IX prophylaxis, have experienced life-threatening bleeding, or have had repeated serious bleeds. Long-term durability data is still accumulating, but the early results represent a fundamental shift in how haemophilia B can be managed, from lifelong infusions to a potential one-time treatment.